Vaxart, Inc.

Vaxart, Inc. is a clinical-stage biotechnology company specializing in the development of oral recombinant protein vaccines. The company's product pipeline includes oral tablet vaccines for norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus. Vaxart is also working on therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company generates revenue through the development and commercialization of its oral vaccine platform, targeting various infectious diseases and cancers.

Products

• Norovirus vaccine

• Seasonal influenza vaccine

• Respiratory syncytial virus vaccine

• Coronavirus vaccine

• Therapeutic vaccines for cervical cancer and dysplasia